

(19) World Intellectual Property Organization
International Bureau




(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/85204 A2

- (51) International Patent Classification⁷: **A61K 39/00**, 47/48, 39/395, A61P 35/00, 31/00
- (74) Agent: **CÔTÉ, France**; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).
- (21) International Application Number: PCT/IB01/01331
- (22) International Filing Date: 11 May 2001 (11.05.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/203,635 11 May 2000 (11.05.2000) US
60/253,671 28 November 2000 (28.11.2000) US
60/253,956 28 November 2000 (28.11.2000) US
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- (71) Applicant: **ALTAREX CORP.** [CA/CA]; University of Alberta, 1123 Dentistry Pharmacy Building, Edmonton, Alberta T6G 2N8 (CA).
- (72) Inventors: **SCHULTES, Birgit**; 12 Monadnock Road, Arlington, MA 02476 (US). **NOUJAIM, Antoine**; 58 Wilkin Road, Edmonton, Alberta T6M 3K4 (CA).
- Published:
— without international search report and to be republished upon receipt of that report
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC METHOD AND COMPOSITION UTILIZING ANTIGEN-ANTIBODY COMPLEXATION AND PRESENTATION BY DENDRITIC CELLS



(57) Abstract: Disclosed are methods and compositions for use in immunotherapy. These methods and compositions are particularly useful for exploiting dendritic cells to present an antigen to a patient, particularly where the patient has a disease associated with the antigen. The invention provides methods for treating a patient having a disease associated with an antigen. The methods according to the invention comprise combining *ex vivo* an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen, wherein the patient receives a therapeutic benefit.

**THERAPEUTIC METHOD AND COMPOSITION UTILIZING ANTIGEN-
ANTIBODY COMPLEXATION AND PRESENTATION BY DENDRITIC
CELLS**

(Attorney Docket No. 107823.185)

5

BACKGROUND OF THE INVENTION

Field of the invention

The invention relates to immunotherapy. More particularly, the invention relates to the use of antigen presenting cells, in particular dendritic cells, in
10 immunotherapy.

Summary of the related art

T lymphocytes (*i.e.*, T cells), unlike B lymphocytes (*i.e.*, B cells), typically recognize their target antigen only when the antigen is presented in the context of the
15 major histocompatibility complex (MHC). Thus, to present antigen to T lymphocytes, which include T helper cells and cytotoxic T cells, the antigen must be presented in context of an MHC molecule on the surface of an antigen presenting cell.

In particular, one type of antigen presenting cell, dendritic cells, has recently become of interest in the area of cancer immunotherapy. Steinman, *Annu. Rev. Immunol.* 9: 271-296 (1991) teaches that dendritic cells are rare leukocytes that originate in the bone marrow and can be found distributed throughout the body. Bjork, *Clinical Immunology* 92: 119-127 (1999) teaches that dendritic cells receive increasing attention due to their potential inclusion as biological adjuvants in tumor vaccines. Dendritic cells express several receptors for the Fc portion of
25 immunoglobulin IgG, which mediate the internalization of antigen-IgG complexes (ICs). In this capacity, dendritic cells are used to present tumor antigens to T cells. Avigan, *Blood Reviews* 13: 51-64 (1999) teaches that several approaches have been adopted to directly load tumor antigens onto dendritic cells, including the pulsing of tumor peptides onto mature dendritic cells. Timmerman *et al.*, *Annu. Rev. Med.* 50:
30 507-529 (1999) teaches that isolated dendritic cells loaded with tumor antigen *ex vivo* and administered as a cellular vaccine have been found to induce protective and therapeutic anti-tumor immunity in experimental animals. European Patent No. EP0553244 describes an antigen/dual-specific binding agent complex for stimulating a

response to the antigen, where the binding agent specifically binds both the antigen and a cell surface receptor on an antigen-presenting cell, but where binding of the binding agent to the cell surface receptor does not block the natural ligand for the receptor.

5 The mechanism of action for dendritic cell antigen presentation has also been explored. Coughlan *et al.*, Veterinary Immunology and Immunopathology 49: 321-330 (1996) discloses that antigen uptake by dendritic cells via Fcγ receptors results in functional augmentation of antigen presentation and T cell proliferation in an *in vitro* sheep system. Regnault *et al.*, J. Exp. Med. 189: 371-380 (1999) teaches that Fcγ
10 receptors induce dendritic cell maturation and promote efficient MHC class I-restricted presentation of peptides from exogenous, immunoglobulin (Ig) complexed antigens in the mouse system.

Thus, there remains a need to discover methods for utilizing dendritic cells to treat human diseases. The promise of dendritic cell-based approaches to treat diseases, such as cancer, underscores the need to actually develop such approaches as effective
15 therapeutic treatments.

BRIEF SUMMARY OF THE INVENTION

The invention provides a therapeutically effective dendritic cell-based approach to the treatment of diseases associated with an antigen. The methods according to the invention comprise combining *ex vivo* an antigen associated with a disease and a
5 dendritic cell binding agent specific for the antigen, with or without a dendritic cell, to provide a composition, and administering the composition to a patient having a disease associated with the antigen, wherein the composition-administered patient receives a therapeutic benefit.

Accordingly, in a first aspect, the invention provides a method for treating a
10 patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising an antigen associated with the disease and a dendritic cell binding agent specific for the antigen, wherein the antigen is complexed to the dendritic cell binding agent and wherein the patient administered the composition receives a therapeutic benefit. Preferably, the patient is
15 human.

In a second aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient a composition comprising an antigen associated with the disease, a dendritic cell binding agent specific for the antigen, and a dendritic cell autologous to the
20 patient, wherein the patient administered the composition receives a therapeutic benefit. Preferably, the patient is a human.

In a third aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising a host anti-xenotypic
25 antibody and a xenotypic antibody specific for the antigen associated with the disease, wherein the patient administered the composition receives a therapeutic benefit.

In a fourth aspect, the invention provides a therapeutic composition comprising a purified dendritic cell binding agent that is specific for an antigen associated with a disease and the antigen associated with the disease. In preferred embodiments, binding
30 of the dendritic cell binding agent to a receptor on a dendritic cell blocks binding of a natural ligand to the receptor. In certain embodiments of the fourth aspect of the invention, administration of the composition to a patient suffering from the disease

provides the patient a therapeutic benefit. Preferably, the patient is a human.
Preferably, the dendritic cell binding agent is an antibody.

In a fifth aspect, the invention provides a therapeutic composition comprising a purified dendritic cell binding agent that is specific for an antigen associated with a disease, a dendritic cell, and the antigen associated with the disease. In preferred
5 embodiments, binding of the dendritic cell binding agent to a receptor on the dendritic cell blocks binding of a natural ligand to the receptor. In certain embodiments, administration of the composition to a patient suffering from the disease provides the patient a therapeutic benefit, wherein the dendritic cell is autologous to the patient.
10 Preferably, the patient is human

In a sixth aspect, the invention provides a therapeutic composition comprising a purified xenotypic antibody that is specific for an antigen associated with a disease and a host anti-xenotypic antibody. In certain embodiments, administration of the composition to a patient suffering from the disease provides the patient a therapeutic
15 benefit, wherein the dendritic cell is autologous to the patient. Preferably, the patient is human

BRIEF DESCRIPTION OF THE DRAWINGS

Figures 1A and 1B show the results of antigen binding studies with monocytes (blue bars) and immature dendritic cells (red bars). Figure 1A is a bar graph showing the percentage of positive events of monocytes or immature dendritic cells following incubation with 1000 U/ml FITC-labeled CA125 antigen and the indicated amount of Alt-2 antibody. Figure 1B is a bar graph showing the mean channel intensity of monocytes or immature dendritic cells following incubation with 1000 U/ml FITC-labeled CA125 antigen and the indicated amount of Alt-2 antibody.

Figure 2 is a bar graph showing the uptake of 1000 U/ml FITC-labeled CA125 antigen in the presence of 0, 0.2, or 0.4 μ g/ml Alt-2 antibody (red bars) or control MOPC-21 antibody (yellow bars).

Figure 3A and 3B are bar graphs showing the percentage of positive events (Figure 3A) and mean channel intensity (Figure 3B) of monocytes (striped bars) or immature dendritic cells (solid bars) incubated with 1000 U/ml FITC-labeled CA125 antigen and the indicated amounts of murine Alt-2 (blue solid and striped bars) or chimeric Alt-2 (red solid and striped bars).

Figures 4A, 4B, and 4C are bar graphs showing the effect of complexation with HAMA (Figure 4A), specific antigen (Figures 4A and 4B), or both (Figure 4C) on antibody binding to dendritic cells. Figure 4A shows the binding of FITC-labeled anti-CA125 antibody, Alt-2, or FITC-labeled anti-PSA antibody, Al-6, to dendritic cells in the presence or absence antigen or in the presence or absence of HAMA. Figure 4B shows the binding of the FITC labeled Alt-2 in the presence of 8000 U/ml CA125 when the concentration of Alt-2 is 0, 0.313, 0.625, 1.25, and 2.5 μ g/ml. Figure 4C show the binding of 1 μ g/ml FITC labeled Alt-2 in the presence of 8000 U/ml CA125 with or without human anti-mouse antibody (HAMA) at 0, 0.33, 1, and 2 μ g/ml.

Figures 5A and 5B are bar graphs showing the uptake of CA125- Alt-2 immune complexes in monocytes and immature dendritic cells in the presence (red solid and striped bars) and absence (blue solid and striped bars) of HAMA as measured by the percentage of positive events (Figure 5A) and mean channel intensity (Figure 5B) for monocytes (striped bars) or immature dendritic cells (solid bars).

Figure 6 is a bar graph showing the *in vitro* T cell activation (both CD4+ (white bars) and CD8+ T cells (black bars)) by dendritic cells "armed" by the indicated

primary stimulation and restimulation as determined by the number of IFN γ producing cells per 10⁶ cells.

Figure 7 is a bar graph showing IFN- γ release from T cells stimulated with DC loaded with CA125, Alt-2, or CA125/Alt-2 complex (*i.e.*, CA125/ α CA125 complex) at the indicated concentrations for a seven day incubation period (round 1; blue bars) or for an initial seven days and an additional seven days with freshly loaded DCs (round 2; red bars).

Figures 8A and 8B are bar graphs showing intracellular IFN- γ production from CD4+ T cells (red bars) or CD8+ T cells (blue bars) stimulated with DC loaded with CA125, Alt-2, or CA125-Alt-2 complex (*i.e.*, CA125/ α CA125 complex) at the indicated concentrations for a seven day incubation period (Figure 8A) or for an initial seven days and an additional seven days with freshly loaded DCs (Figure 8B).

Figure 9 is a bar graph showing the *in vitro* T cell activation (both CD4+ and CD8+ T cells) to peptides generated by dendritic cells "armed" by the indicated primary stimulation and restimulation. T cell activation was determined by the number of IFN γ producing cells per 10⁶ cells.

Figures 10A and 10B show the rate of complexation of anti-CA125 antibody, Alt-2, to circulating CA125 following injection of Alt-2. Specifically, Figure 10A is a bar graph comparing the levels of CA125/ α CA125 complex (black bars) compared to the level of free circulating CA125 (dotted bars). Figure 10B is a line graph showing the rate of complexation of anti-CA125 antibody, Alt-2, to circulating CA125 following injection of Alt-2 (left side of the graph), and the amount of free Alt-2 antibody (green circles) cleared following injection time, as measured in percentage of the injected dose (%ID). With time, the percentage of free circulating CA125 decreases as the amount of complexed CA125 increases.

Figures 11A, 11B, and C are graphs showing the relationship between CA125 antigen specific B cell (Figure 11A) and T cell (Figures 11B and 11C) responses, CA125 level, and patient survival. Specifically, Figure 11A shows the induction of humoral anti-CA125 response (y-axis) as compared to the level of circulating CA125 antigen present at the time of injection of the anti-CA125 antibody, Alt-2 (x-axis). Figure 11B shows the induction of a cellular anti-CA125 response (y-axis) as compared to the level of circulating CA125 antigen (x-axis), comparing pre-injection

of Alt-2 (open triangles) to post-injection of Alt-2 (closed triangles). Figure 11C is a scatter graph showing the stimulation index of T cells (CA125-specific T cell proliferation) in patient before (pre) or after (post) Alt-2 injection, where patients having greater than 105 U/ml CA125 had the greatest T cell response.

5 Figure 12 is a bar graph showing the multi-epitopic nature of the response from anti-CA125 antibodies produced by thirteen patients.

Figures 13A and 13B are survival curves of patients receiving injection of Alt-2. Specifically, Figure 13A is a survival curve showing an increased survival in patients who developed a 3x increase in anti-CA125 antibody response following injection of Alt-2 (dotted line) as compared to those with developed a less than 3x increase in anti-CA125 antibody response following injection of Alt-2 (solid line).
10 Figure 13B is a survival curve showing an increased survival in patients who developed a CA125-specific T cell response following injection of Alt-2 (dotted line) as compared to those who did not develop a CA125-specific T cell response following injection
15 (solid line).

Figures 14A-14B show the preferential presentation of antigen complexed with antibody by antigen presenting cells such as macrophages and B cells. Specifically, Figure 14A is a bar graph showing the level of T cell proliferation as measured by the Stimulation Index (SI) using macrophages as antigen-presenting cells following
20 stimulation by the CA125, Alt-2, B27.1, mIgG1, CA125 plus Alt-2, CA125 plus B27.1, and CA125 plus mIgG1 at 0.1 µg/ml (black dots on white bars), 1 µg/ml ((white dots on black bars), and 10 µg/ml (solid black bars). Figure 14B is a bar graph showing the level of T cell stimulation as measured by the Stimulation Index (SI) using B cells as antigen-presenting cells following stimulation by the CA125, Alt-2, B27.1,
25 mIgG1, CA125 plus Alt-2, CA125 plus B27.1, and CA125 plus mIgG1 at 0.1 µg/ml (black dots on white bars), 1 µg/ml ((white dots on black bars), and 10 µg/ml (solid black bars).

Figure 15 is a bar graph showing the different levels of human IgG in reconstituted SCID/bg mice.

30 Figure 16 is a bar graph showing the different tumor volumes in mice treated with control IgG1 (yellow bars), Alt-6 only (green bars), PSA only (blue bars), and the PSA/α-PSA immune complex (red bars).

DETAILED DESCRIPTION OF THE PREFERRED EMBODIMENTS

The invention relates to immunotherapy. More particularly, the invention relates to the use of antigen-presenting cells, in particular dendritic cells, in immunotherapy. The invention provides a therapeutically effective dendritic-based approach to the treatment of diseases associated with an antigen. The patents and publications cited herein reflect the level of skill in this field and are hereby incorporated by reference in their entirety to the same extent as if each was specifically and individually indicated to be incorporated by reference. In the case of any conflict between a cited reference and this specification, this specification shall prevail.

The invention provides methods for treating a patient having a disease associated with an antigen. The methods according to the invention comprise combining *ex vivo* the antigen associated with the disease with a dendritic cell binding agent specific for the antigen to provide a composition, and administering the composition to a patient suffering from the disease associated with the antigen, wherein the patient receives a therapeutic benefit.

Accordingly, in a first aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition of an antigen associated with the disease and a dendritic cell binding agent specific for the antigen, wherein the antigen is complexed to (*i.e.*, specifically bound by) the dendritic cell binding agent, and wherein the patient administered the composition receives a therapeutic benefit.

In certain embodiments, an antigen/dendritic cell binding agent complex may be formed, for example, by combining *ex vivo* the antigen and the dendritic cell binding agent. By “combining *ex vivo*” means bringing into physical proximity outside of the body.

In certain preferred embodiments, the patient is a human. In other embodiments, the patient is preferably a non-human mammal, particularly a laboratory animal. Preferred non-human patients of the invention include, without limitation, mice, rats, rabbits, non-human primates (*e.g.*, chimpanzees, baboons, rhesus monkeys), dogs, cats, pigs, and armadillos.

The methods according to the invention are useful for therapeutically treating patients having a disease associated with an antigen. As used herein, the term “disease

associated with an antigen” means a condition in which signs or symptoms of illness in a majority of patients are present when the antigen is present in the patient’s body at a certain concentration, but in which signs or symptoms of illness are absent or reduced when the antigen is absent from the patient’s body or present in the patient’s body at a lower concentration. “Signs or symptoms of illness” are clinically recognized manifestations or indications of disease.

It will be appreciated that a “patient suffering from a disease associated with an antigen” of the invention may not yet be symptomatic for the disease. Accordingly, a patient with circulating BRCA-1 is a patient according to the invention even though that patient may not yet be symptomatic for breast cancer or other adenocarcinoma.

Some non-limiting examples of such antigens associated with a disease include the prostate specific antigen (associated with prostate cancer), BRCA-1 and BRCA-2 antigens (associated with many adenocarcinomas, including breast cancer, lung cancer, and pancreatic cancer), CA125 (associated with ovarian cancer), aberrant myelin basic protein (associated with Alzheimer’s disease), gp120 (associated with HIV infection and AIDS), MUC-1 (associated with breast cancer), EBNA-1 (associated with Epstein Barr Virus infection), CA19.9 (associated with colorectal, stomach, and pancreatic cancers), and TAG-72 (associated with ovarian, stromal, and pancreatic cancers), p53 (associated with various cancers).

Thus, in certain preferred embodiments, the antigen is a tumor-associated antigen. A “tumor associated antigen” is an antigen in the patient’s body that is made by tumor cells, and which may be presented on the tumor surface, or circulating, or both. Preferred tumor-associated antigens include, without limitation, CA125, PSA, MUC-1, CA19.9, and TAG-72. Generally from about 0.1 to about 50 µg antigen are used.

In certain preferred embodiments, the antigen is from a pathogen. A “pathogen” is an etiolytic agent capable of causing disease. Preferred pathogens include, without limitation, viruses (*e.g.* hepatitis B, hepatitis C, herpes, and HIV-1), viroids, bacteria, fungi, prions, and parasites.

“Specifically bound to the antigen” or “specific for the antigen” means that the dendritic cell binding agent binds to the antigen with greater affinity than it binds unrelated proteins. Preferably such affinity is at least 10-fold greater, more preferably

at least 100-fold greater, and most preferably at least 1000-fold greater than the affinity of the binding agent for unrelated proteins. Preferably, an antigen presenting cell binding agent that is specific for an antigen forms an association with that antigen with an affinity of at least $10^6 M^{-1}$, more preferably, at least $10^7 M^{-1}$, even more preferably, at least $10^8 M^{-1}$, even more preferably, at least $10^9 M^{-1}$, and most preferably, at least $10^{10} M^{-1}$ either in water, under physiological conditions, or under conditions which approximate physiological conditions with respect to ionic strength, *e.g.*, 140 mM NaCl, 5 mM $MgCl_2$.

The injected dendritic cell binding agent complexed to a circulating antigen is targeted *in vivo* to dendritic cells (which are preferably immature dendritic cell) through Fc receptors present on the surface of these dendritic cells. By targeting antigen to preferably immature dendritic cells and presentation of these antigens on both MHC class I and class II molecules, the immune complex of the binding agent/antigen efficiently sensitize dendritic cells to induce activation of both CD4(+) helper and CD8(+) cytotoxic T cells *in vivo*.

A "dendritic cell binding agent" of the invention binds to the ligand-binding site of a receptor on the surface of a dendritic cell, at any stage of development of the dendritic cell. Preferably, once the dendritic cell binding agent is bound to the ligand-binding site of the dendritic cell receptor, the natural ligand cannot bind to the receptor at the same time that the dendritic cell binding agent binds to the receptor. Preferably, the dendritic cell binding agent binds to the receptor on the surface of a dendritic cell when the binding agent is specifically bound to an antigen. Preferably, such binding causes internalization of the binding agent/antigen complex. Even more preferably, binding and/or internalization of the binding agent/antigen complex by an immature or precursor dendritic cell causes maturation and/or activation of the dendritic cell.

Preferably, the dendritic cell binding agent of the invention binds to an activating Fc γ receptor, such as CD64 (Fc γ RI) or CD32 (Fc γ RIIA) that is not abundant on neutrophils.

As used herein, by "ligand-binding site of a receptor" is meant the site on the receptor to which the natural ligand of the receptor binds. For example, if the receptor is a Fc γ type II receptor, the natural ligand for the receptor is an IgG antibody. A dendritic cell binding agent of the invention, when bound to a receptor, blocks the

ligand-binding site of the receptor such that the natural ligand for that receptor cannot bind the receptor. In one non-limiting example, if the receptor is a Fc γ type II receptor and the dendritic cell binding agent of the invention is an IgG antibody, then binding of the dendritic cell binding agent of the invention to the receptor prevents other IgG
5 antibodies from binding to the receptor.

Accordingly, dendritic cell binding agents of the invention are readily identified by art-known methods. In one non-limiting example, where the dendritic cell binding agent is an IgG antibody, a precursor, immature, or mature dendritic cell is purified as described below. Next, the cell is incubated with the FITC-labeled IgG antibody (with
10 or without the antigen to which the antibody specifically binds). Next, the phycoerythrin (PE)-labeled natural ligand (*i.e.*, another IgG antibody) is added to the cell. The cell can then be subjected to analysis by flow cytometry to determine if the FITC-labeled IgG antibody of the invention is able to block binding of the PE-labeled antibody to the receptor on the dendritic cell.

15 In certain preferred embodiments, the dendritic cell binding agent is not a bispecific antibody which has two antigen binding sites, one that is specific for the antigen of the invention and the other that is specific for the receptor, *e.g.*, at its ligand-binding site, on the surface of a dendritic cell.

“Administering the composition to a patient” means providing the composition
20 to the patient in a manner that results in the composition being inside the patient’s body. Such an administration can be by any route including, without limitation, subcutaneous, intradermal, intravenous, intra-arterial, intraperitoneal, and intramuscular. “Receives a therapeutic benefit” means that the patient experiences alleviation or reduction of signs or symptoms of illness, and specifically includes, without limitation,
25 prolongation of survival. In certain preferred embodiments of the methods according to the invention, a CD8+ IFN- γ producing T cell is activated to induce a cytotoxic T lymphocyte (CTL) immune response in the patient administered the composition. In certain embodiments of the methods according to the invention, a CD4+ IFN- γ producing T cell is activated to induce a helper T cell immune response in the patient
30 administered with the composition. These activated CD4+ IFN- γ producing T cells (*i.e.*, helper T cells) provide necessary immunological help (*e.g.*, by release of cytokines) to induce and maintain not only CTL, but also a humoral immune response

mediated by B cells. Thus, in certain embodiments of the methods according to the invention, a humoral response to the antigen is activated in the patient administered with the composition.

Activation of a CD8+ and/or CD4+ IFN- γ producing T cells means causing T
5 cells that have the ability to produce IFN- γ to actually produce IFN- γ , or to increase their production of IFN- γ . "Induction of CTL" means causing potentially cytotoxic T lymphocytes to exhibit antigen-specific cytotoxicity, or to increase such antigen-specific cytotoxicity. "Antigen-specific cytotoxicity" means cytotoxicity against a cell that is presenting the antigen that is greater than cytotoxicity against a cell that is not
10 presenting the antigen. "Cytotoxicity" refers to the ability of the cytotoxic T lymphocyte to kill the target cell. Preferably, such antigen-specific cytotoxicity is at least 3-fold, more preferably 10-fold greater, more preferably more than 100-fold greater than cytotoxicity against a cell that is not presenting the antigen.

In certain preferred embodiments, the dendritic cell binding agent of the
15 invention binds to the antigen and an Fc γ type II or type I receptor on the dendritic cells. Preferably, binding of the binding agent to the Fc γ type II or type I receptor blocks the binding of the natural ligand to, respectively, the Fc γ type II or type I receptor. Accordingly, in certain embodiments, the dendritic cell binding agent binds to the antigen and to an Fc γ Type I (CD64) receptor on a dendritic cell in the patient
20 administered with the composition. In certain embodiments, the dendritic cell binding agent binds to the antigen and to an Fc γ Type II (CD32) receptor, such as a Fc γ Type IIA (CD32A) receptor or a Fc γ Type IIB (CD32B) receptor on a dendritic cell in the patient administered with the composition. In certain embodiments, the dendritic cell binding agent binds to the antigen and to an Fc γ Type II CD16 (Fc γ RIII) receptor on a
25 dendritic cell in the patient administered with the composition.

In certain preferred embodiments, the dendritic cell binding agent of the invention is an antibody. Preferably the antibody is provided at a concentration of from about 1-10 μ g/ml. An "antibody" includes a molecule comprising an active portion of an antibody. "An active portion of an antibody" is a molecule that includes
30 an antigen binding site that is specific for an antigen and a receptor binding site that binds an Fc receptor on its ligand-binding site (*e.g.*, the Fc portion of the antibody included the heavy chain constant region). Accordingly, an antibody of the invention

may be, *e.g.*, chimeric, single chain, mutant, or antibody fragment so long as the antibody is able to specifically bind an antigen and so long as the antibody includes a portion that binds an Fc receptor on its ligand-binding site.

Accordingly, an antibody of the may be encoded by an immunoglobulin gene
5 having specific point mutation in the part of the gene encoding the receptor binding site. In one non-limiting example, the gene encoding the anti-PSA antibody, Alt-6, can be subjected to point mutation in the portion of the gene encoding the receptor binding site. The resulting antibody mutants can be screened on cells (*e.g.*, COS or HeLa cells) transfected with a gene encoding the Fcγ Type I (CD64) receptor, the Fcγ Type
10 II (CD32) receptor, or the Fcγ Type II CD16 (FcγRIII) receptor. A preferred mutant Alt-6 antibody of the invention is one which binds better (*i.e.*, by greater numbers or with higher affinity) to a cell expressing the Fcγ Type I (CD64) receptor, Fcγ Type II (CD32) receptor and/or the Fcγ Type II CD16 (FcγRIII) receptor as compared to a cell not expressing one of these receptors.

15 In certain embodiments, the dendritic cell binding agent of the composition includes a portion that elicits a human anti-xenotypic antibody (HAXA) response.

In certain embodiments, the dendritic cell binding agent is a xenotypic antibody. A “xenotypic antibody” is an antibody from a species other than the patient’s species. For example, if the patient is a human, a dendritic binding agent of the invention that is
20 a murine antibody is a xenotypic antibody. Similarly, if the patient is a mouse, a dendritic binding agent of the invention that is a rat antibody is a xenotypic antibody. Preferred xenotypic antibodies include monoclonal antibodies, including without limitation murine monoclonal antibodies. Particularly preferred murine monoclonal antibodies include Alt-1 (murine IgG1, specifically binds to MUC-1; ATCC No. PTA-
25 975; American Type Culture Collection, Manassas, VA), Alt-2 (murine IgG1, specifically binds to CA125; ATCC No. PTA-1883), Alt3 (murine IgG3, specifically binds to CA19.9; ATCC No. PTA-2691), Alt-4 (murine IgM, specifically binds to CA19.9; ATCC No. PTA-2692), Alt-5 (murine IgG1, specifically binds to CA19.9; ATCC No. PTA-2690); and Alt-6 (murine IgG1, specifically binds to prostate specific
30 antigen (PSA); ATCC No. HB-12526).

In certain embodiments, the xenotypic antibody elicits a host anti-xenotypic antibody (HAXA) response in the patient.

In certain preferred embodiments, the composition administered to the patient further includes host anti-xenotypic antibodies (HAXA). "Host anti-xenotypic antibodies (HAXA)" are antibodies of the host animal species that bind to the xenotypic antibody contained in the composition of the invention. For example, if the patient is a human and the xenotypic antibodies are rabbit antibodies, the HAXA is human anti-rabbit antibodies. Preferably the HAXA is provided in the composition at a concentration of from about 1-10 µg/ml. Preferred HAXA include, without limitation, human anti-mouse antibody (HAMA).

In certain embodiments, if the composition administered to the patient does not include HAXA, HAXA is preferably already present in the patient's blood. Such a patient may already have HAXA if, for example, the patient has been previously treated with a non-specific antibody of the same species as the dendritic cell binding agent of the invention. For example, prior to the administration of the composition of the invention comprising the dendritic cell binding agent and the antigen, a human patient may be administered with a polyclonal murine antibody with no defined specificity (or with a murine monoclonal antibody that specifically binds to, for example, an egg shell protein not expressed in humans). Once HAMA is detectable in the patient's blood, the composition is administered to the patient.

In further embodiments, the composition of the first aspect further comprises a dendritic cell. Preferably, the dendritic cell is autologous to the patient.

As used herein, by "dendritic cell" is meant a bone marrow-derived cell that can internalize antigen and process the antigen such that it (or a peptide derived from the antigen) is presented in the context of both the MHC class I complex and the MHC class II complex. Accordingly, a dendritic cell of the invention is able to activate both CD8+ T cells (which are primarily cytotoxic T lymphocytes) and CD4+ T cells (which are primarily helper T cells). It should be understood that any cell capable of presenting a peptide derived from an internalized antigen on both class I and class II MHC is a dendritic cell of the invention. Preferably, a dendritic cell of the invention has the phenotype and characteristics of the dendritic cells described in Steinman, Annu. Rev. Immunol. 9: 271-296 (1991).

In certain preferred embodiments, the dendritic cell, when added to the composition, is an immature dendritic cell. As used herein, by "immature dendritic

cells” means a population of dendritic cells preferably having one or more of the following cell surface antigens at the indicated level of expression: CD11c present on greater than about 90% of the dendritic cells in the population, HLA-DR present on fewer than about 90% of the dendritic cells in the population but on greater than about 70% of the dendritic cells in the population, HLA-ABC present on from about 80% to about 90% of the dendritic cells in the population, CD14 present on fewer than about 20% of the dendritic cells in the population, CD16 present on greater than about 10% to about 40% of the dendritic cells in the population, CD80 present on about 50% to about 70% of the dendritic cells in the population, CD86 present on greater than about 40% to about 70% of the dendritic cells in the population, CD83 present on greater than about 10% to about 20% of the dendritic cells in the population, CD64 present on greater than about 40% to about 60% of the dendritic cells in the population, and CD32 antigen present on from about 70% to about 95% of the dendritic cells in the population, and about less than 10% of the dendritic cells in the population are CD3/CD19 positive (*i.e.*, about less than 10% have CD3/CD19 expression).

In certain preferred embodiment, the dendritic cell, when added to the composition, is a precursor dendritic cell. As used herein, by “precursor dendritic cells” means a population of cells, each of which is capable of becoming a dendritic cell, where greater than 80% of the population have CD64 and CD32 antigen present and about 70% of the population is positive for CD14.

In the embodiments of the invention where the dendritic cell, when added to the composition, is either an immature dendritic cell or is a precursor dendritic cell, the composition is preferably incubated *ex vivo* under conditions (*e.g.*, in cell culture) that allow for maturation of the immature dendritic cell or precursor dendritic cell prior to administering the composition to the patient. Such conditions that allow the formation of mature dendritic cells from immature or precursor dendritic cells are described below in the examples.

In the embodiments of the invention where the dendritic cell is included in the composition, and where the patient is human, the dendritic cell preferably expresses the cell surface molecules described below in Table I at its different maturation stages. Note that expression of the Fc receptors, particularly the CD64 (FcγRI) typically decreases as the DC mature.

Table I
Human Dendritic Cell Surface Markers

	Day 0	Day 4	Day 7
Marker (all cells)	<i>Monocytes</i>	<i>immature DC</i>	<i>mature DC</i>
HLA-DR	70-85%	80-85%	95-99%
HLA-ABC	70-85%	85-90%	95-99%
CD3	1-5%	ND	ND
CD4	2-3%	ND	ND
CD8	2-3%	ND	ND
CD16	3-15%	15-40%	0.5-5%
CD19	5-10%	ND	ND
CD14	75-80%	0.4-0.5%	0.1-0.2%
CD11c	75-80%	95-99%	99-100%
Marker (gated on DC)			
CD86	85-90%	40-70%	95-99%
CD80	30-50%	55-80%	85-90%
CD40	40-50%	55-60%	55-60%
CD83	10-15%	10-15%	55-60%
CD32	89-98%	70-95%	40-45%
CD64	92-99%	28-60%	4-10%

One non-limiting method to obtain dendritic cells according to the invention is described below in Example I.

- 5 Accordingly, in one non-limiting method, 10 μ g of CA125 and 5 μ g of the murine monoclonal antibody that specifically binds to CA125, Alt-2, are combined together *ex vivo*. In a variation of the method, human anti-murine antibodies are added to the mixture. Then, the mixture is added to immature dendritic cells prepared as described below from the patient suffering from the disease. The addition of the
- 10 antigen (in this case CA125 plus α CA125 antibody, Alt-2) promotes maturation of the immature dendritic cells. (Note that as used throughout, the symbol " α " means "anti-". Thus, " α CA125" means "anti-CA125"). Next, the matured dendritic cells "loaded" or "armed" with CA125 and Alt-2 (and, in some cases, HAMA) are removed from culture and administered to the patient.
- 15 Note that the dendritic cell used in the invention is preferably autologous to the patient to whom the composition of the invention is administered. By "autologous" is meant having identically matched MHC loci (both class I and class II). Thus, an identical sibling can provide autologous dendritic cells for a patient. Similarly, a close relative can provide autologous dendritic cells for a patient, so long as the patient and
- 20 the close relative have identically matched MHC loci. Of course, two individuals of an

inbred strain of laboratory animal (*e.g.*, inbred Balb/c mice) are autologous to one another.

In certain preferred embodiments, if the patient to whom the composition of the invention is administered already had an immune response to the antigen, following
5 administration, the immune response is shifted predominantly from a helper to a cytotoxic T cell response, thus providing the patient, following administration, a therapeutic benefit

Thus, in one non-limiting example, a patient of the invention with prostate cancer may already have either antibodies that are specific for prostate specific antigen
10 (PSA) and/or helper T cells that are specific for PSA. However, following administration of the composition of the invention, the PSA of the composition is internalized and presented on antigen presenting cells in such a way (*e.g.*, in context of MHC class I) that cytotoxic T cells that are specific for PSA are stimulated, thereby providing the patient a therapeutic benefit as compared to the patient's condition prior
15 to administration of the composition.

In a second aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient a composition comprising an antigen associated with the disease, a dendritic
20 cell binding agent specific for the antigen, and a dendritic cell autologous to the patient, wherein the patient administered the composition receives a therapeutic benefit. Preferably, the patient is a human

In some embodiments, the dendritic cell, when combined with the antigen and the dendritic cell binding agent, is either a precursor dendritic cell or an immature
25 dendritic cell. In these embodiments, the composition is incubated *ex vivo* under conditions that allow for maturation of the immature dendritic cell prior to administering the composition to the patient.

In some embodiments, the antigen and dendritic cell binding agent may be combined simultaneously with the dendritic cell to make the composition. In some
30 embodiments, the dendritic cell binding agent and the antigen are combined with one another before they are combined with the dendritic cell to make the final composition. In these embodiments, the composition including the dendritic cell is then administered to the patient suffering from the disease.

In certain embodiments, where the dendritic cell binding agent is a xenotypic antibody and the composition further comprises human anti-xenotypic antibodies.

In a third aspect, the invention provides a method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising a host anti-xenotypic antibody and a xenotypic antibody specific for the antigen associated with the disease, wherein the patient administered the composition receives a therapeutic benefit.

In a fourth aspect, the invention provides a therapeutic composition comprising a purified dendritic cell binding agent that is specific for an antigen associated with a disease and the antigen associated with the disease. Preferably, binding of the dendritic cell binding agent to a receptor on a dendritic cell blocks binding of a natural ligand to the receptor.

In a fifth aspect, the invention provides a therapeutic composition comprising a purified dendritic cell binding agent that is specific for an antigen associated with a disease, a dendritic cell, and the antigen associated with the disease. Preferably, binding of the dendritic cell binding agent to a receptor on the dendritic cell blocks binding of a natural ligand to the receptor. Preferably, the dendritic cell of the composition is autologous to a patient to whom the composition is administered.

In a sixth aspect, the invention provides a therapeutic composition comprising a purified xenotypic antibody that is specific for an antigen associated with a disease and a host anti-xenotypic antibody.

As used herein, by "purified" is meant that the indicated agent (*e.g.*, a purified dendritic cell binding agent or xenotypic antibody) has been separated from components which naturally accompany it. For example, in the case of a protein (*e.g.*, a dendritic cell binding agent), the purified protein is separated from components, such as other proteins or fragments of cell membrane, that accompany it in the cell. Of course, those of ordinary skill in molecular biology will understand that water, buffers, and other small molecules may additionally be present in a purified protein preparation. A purified protein (*e.g.*, a purified dendritic cell binding agent) of the invention is at least 95% by weight, more preferably at least 98% by weight, even more preferably at least 99% by weight, and most preferably 100% by weight free of components which naturally accompany the nucleic acid molecule or polypeptide.

According to the invention, a purified dendritic cell binding agent of the invention may be generated, for example, by recombinant expression of a nucleic acid molecule encoding the dendritic cell binding agent in a cell in which the dendritic cell binding agent does not naturally occur. Of course, other methods for obtaining a
5 purified dendritic cell binding agent of the invention include, without limitation, artificial synthesis of the dendritic cell binding agent on a peptide synthesizer and isolation of the dendritic cell binding agent from a cell in which it naturally occurs using, *e.g.*, an antibody that specifically binds to the dendritic cell binding agent. In the case where the dendritic cell binding agent is a monoclonal antibody, a purified
10 dendritic cell binding agent can be obtained from the culture supernatant of the hybridoma which secretes the dendritic cell binding agent, or from ascites fluid from an animal injected with the hybridoma.

Preferably, the therapeutic compositions of the fourth, fifth, and sixth aspects of the invention further comprise a pharmaceutically acceptable carrier. By
15 “pharmaceutically acceptable carrier” is meant a carrier that is physiologically acceptable to the administered patient and that retains the therapeutic properties of the dendritic cell binding agent and antigen (and/or dendritic cell) with which it is administered. One exemplary pharmaceutically acceptable carrier is physiological saline. Other pharmaceutically-acceptable carriers and their formulations are well-
20 known and generally described in, for example, Remington’s Pharmaceutical Sciences (18th Edition, ed. A. Gennaro, Mack Publishing Co., Easton, PA, 1990).

Preferably, administration of the therapeutic compositions of the fourth, fifth, and sixth aspects of the invention to a patient suffering from the disease provides the patient a therapeutic benefit. Preferably, the patient is a human.

25 The following examples are intended to further illustrate certain particularly preferred embodiments of the invention and are not intended to limit the scope of the invention.

Example I

Isolation of Dendritic Cells

30

To isolate dendritic cells, peripheral blood mononuclear cells (PBMC) were isolated from the apheresis products from normal volunteers by ficoll-hypaque (Histopaque 1.077, commercially available from Sigma, St. Louis, MO) gradient

centrifugation, and viably frozen using an automated cell freezer (commercially available from Gordinier Electronics, Roseville, MI) in RPMI (commercially available from Life Technologies, Frederick, MD) containing 40% human antibody serum (commercially available from Gemini Bio-Products, Woodland, CA) and 10% DMSO (Sigma). The cells were stored in the vapor phase of liquid nitrogen until used. DNA was prepared from a portion of the cells and used for molecular HLA typing.

Next, dendritic cells (DC) were isolated by negative selection. To do this, DC precursors were prepared from freshly-thawed PBMC by negative selection using immunomagnetic bead depletion. Specifically, PBMC were placed into a tube and incubated on ice for 30 min. with mouse anti-human CD3, CD16, and CD19 antigens (commercially available from Caltag, Burlingame, CA). Excess antibody was removed by washing the cells with phosphate buffered saline containing 1% of bovine serum albumin (PBS/0.1% BSA), and the washed cells were next incubated with Pan Mouse IgG immunomagnetic beads (commercially available from Dynal, Lake Success, NY) for 30 min. on ice. The tube containing the cells plus specific mouse anti-human antigens and the Pan Mouse IgG immunomagnetic beads was placed against a magnet to remove the cell:bead complexes. The cells that bound to the magnet were either T cells, B cells, or Natural Killer (NK) cells. Accordingly, the supernatant contained the lineage-depleted DC precursors (*i.e.*, the monocytes remaining in the fluid in the tube not expressing CD3, CD16, or CD19 antigens and so not bound by the magnet). These negatively selected cells were approximately 70% pure monocytes as characterized by Flow cytometry using a broad CD marker panel (see Table I above) were collected.

Next, the negatively selected cells were washed, resuspended in cRPMI (RPMI supplemented with 1% glutamine and 10% heat-inactivated human serum (from a person with blood type AB)) containing GM-CSF (1000 U/ml) and IL-4 (1000 U/ml) (both commercially available from R & D Systems, Minneapolis, MN) and cultured at 37°C in 5% CO₂ at 0.5 x 10⁶ cells/well in 24 well plates for four days. These cells were immature dendritic cells by day four, and analyzed for surface expression of numerous cell surface antigens by flow cytometry see Table I above).

On the fourth day of culture, the cells were pulsed with antigen (*e.g.*, Prostate Specific Antigen (PSA)) and incubated for an additional three days. (Note that the

antigen which the DC cells were pulsed with was dependent upon what the DC cells would be eventually used for. For example, if the DC cells were to be used to generate a T cell response to PSA, the DC cells would be pulsed with PSA antigen.) Several agents which are known to cause DC precursors to mature into mature DC cells were added to the cultures eight hours after addition of the antigen. These agents included TNF α (10 μ g/ml) and/or IFN α (50 μ g/ml). The matured DC were harvested on the seventh day of culture, analyzed for phenotypic markers by flow cytometry and used in functional studies.

To analyze DC for cell surface marker expression by flow cytometry, standard methods were employed. Briefly, the cells were aliquotted into polystyrene tubes and stained for surface markers with fluorochrome-labeled murine antibodies. The complete DC cell surface marker panel included: HLA-A, HLA-A B, HLA-A C, HLA-DR, CD14, CD11c, CD123, CD4, CD40, CD83, CD86, CD80, CD16, CD32, CD64 (specific detectably labeled antibodies to which are commercially available from Becton Dickinson, San Jose, CA). Following a 30 min. incubation on ice, the cells were washed with PBS and pelleted by centrifugation. The cell pellets were resuspended in 250 μ l of fixative (2% paraformaldehyde). The data was acquired using a FACSCan flow cytometer (Becton Dickinson, San Jose, CA) and analyzed with Cellquest software (Becton-Dickinson, San Jose, CA).

Example II

Phenotypic Markers on Dendritic Cells

Initial studies were focused on the uptake of CA125 in monocytes and dendritic cells in the presence or absence of Alt-2. For this purpose, CA125 was purified from tissue culture supernatant of NIH:OVCAR-3 cells (AltaRex Corp.). Highly purified CA125 was labeled with Fluorescein (Flourescein-EX, Molecular Probes), and incubated with monocytes, immature dendritic cells, and mature dendritic cells under various conditions. In some experiments, the uptake of MAb-Alt-2 was also followed, where the MAb-Alt-2 was labeled with Fluorescein-EX or Cy-3.

As shown above in Table I, monocytes, immature DC, and mature DC could be easily distinguished based on their expression of various cell surface antigens.

Example III

Comparison of CA125 Antigen Uptake in Monocytes to Immature Dendritic Cells

In these studies, highly purified CA125 was labeled with Fluorescein and
5 incubated with monocytes or immature dendritic cells at 1000 U/mL for 1 hour at
37°C. In some cases, unlabeled antibody was added simultaneously with the labeled
antigen to study the effect of complex formation on the uptake by the two antigen-
presenting cells. The binding to cells was quantified by flow cytometry and the results
are shown in Figures 1A (percent positive events) and 1B (mean channel intensity). As
10 shown in Figures 1A and 1B, immature dendritic cells showed much higher uptake of
the antigen, with MAb Alt-2 as compared to without MAb Alt-2. Both monocytes and
immature dendritic cells showed an increase of CA125 uptake in the presence of MAb
Alt-2 (see Figures 1A and 1B, respectively). For the immature dendritic cells, the
CA125 concentration needed to be lowered to 1000 U/mL to allow the detection of an
15 antibody effect (concentration below the saturation point for CA125 uptake).

It is interesting to note that immature DCs showed an increase in the number of
cells capable of taking up the CA125 antigen (Figure 1A, % positive cells) as well as
the concentration of antigen within each cell (Figure 1B, mean fluorescence intensity)
with increasing concentrations of MAb Alt-2. In monocytes, increasing antibody
20 concentrations could only enhance the percentage of cells capable of taking up the
CA125 antigen. These results may indicate that the immune complexes are either
taken up by different receptors in monocytes and immature DCs or that the immune
complexes are taken up by the same receptors in monocytes and immature DCs, but
the receptor is recycled at a higher frequency in immature DCs. The receptor is
25 certainly more abundant and/or is internalized more rapidly in immature DCs than
monocytes, demonstrated by the higher percentage of targeted cells in DCs (see Figure
1A).

Next, the requirement for antibody specificity was tested. To do this, highly
purified CA125 was labeled with Fluorescein and incubated with immature dendritic
30 cells at 1000 U/mL for 1 hour at 37°C in the absence and presence of unlabeled MAb
Alt-2 or MOPC-21 (a control murine IgG1 that does not bind to the CA125 antigen).
The binding to cells was assessed by flow cytometry, and the results are shown in
Figure 2. As Figure 2 shows, antibody-enhanced uptake of CA125 was specific for

MAB Alt-2 and could not be achieved with a control antibody that does not bind to CA125. Consequently, the antibody-enhanced uptake is due to a more efficient uptake route in DCs and not due to stimulation of the endocytotic activity of dendritic cells upon receptor engagement by the binding MOPC-21 antibody

5

Example IV

Effect of Murine Alt-2 and Chimeric Alt-2 on CA125 Antigen Uptake

Other binding studies have compared the uptake of CA125 in the presence of a murine and humanized form of MAB Alt-2. In this study, fluorescein-labeled CA125 was incubated with monocytes and immature DCs at 1000 U/mL for 1 h at 37°C in the presence of murine (mAlt-2) and chimeric Alt-2 (cAlt-2 (chimeric with a human IgG3 constant region)). The binding to cells was assessed by flow cytometry.

As shown in Figures 3A and 3B, the chimeric antibody showed slightly better enhancement of CA125 binding to monocytes than the murine Alt-2; on immature dendritic cells, the murine and chimeric antibody were equally effective. As for the murine antibody, the chimeric Alt-2 increased the percentage of CA125-targeted cells within the monocytes (Figure 3A) and dendritic cell populations, but increased the amount of CA125 per cell only in dendritic cells (Figure 3B).

20

Example V

Effect of HAMA on CA125 Antigen Uptake

Complexation of antibody with specific antigen or with HAMA and binding to dendritic cells was measured. To do this, human anti-mouse antibody (HAMA) was purified from patient serum samples with high HAMA concentrations after MAB Alt-2 injection via affinity chromatography on Protein G, and a MAB-AR20.5 column, followed by negative selection on a MAB Alt-2 column to eliminate Ab2 (*i.e.*, human antibody that binds to the idiotype of the MAB Alt-2 antibody).

Five micrograms (5 µg) FITC-labeled Alt2 (anti-CA125) or Alt-6 (anti-PSA) murine monoclonal antibody was incubated together with the corresponding antigen (1 µg) and/or HAMA (2.5 µg) and 5×10^5 dendritic cells at 37°C for 60 minutes. The mixture was then washed once and resuspended in 0.5% formalin + PBS and subjected to FACScan on a FACSCalibur machine (Beckton-Dickinson). The results for Alt-2

and CA125 are shown in Figures 4A, 4B, and 4C. These results demonstrate that binding of antibody to dendritic cells is enhanced by complexation of antibody to its antigen, complexation of antibody with HAMA, or complexation of antibody to its antigen in the presence of HAMA.

5 Further binding studies were conducted to compare the uptake of the CA125-MAb-Alt-2 complex by monocytes or immature dendritic cells in the presence and absence of HAMA. In this study, fluorescein-labeled CA125 + murine MAb-Alt-2 was incubated at 1000 U/ml of CA125 and a range of MAb-Alt-2 concentrations with monocytes or immature dendritic cells for 1 hour at 37°C. The binding studies were
10 conducted in the absence and presence of human anti-mouse antibodies (HAMA). The HAMA concentrations were equivalent to the MAb-Alt-2 concentrations to form equimolar complexes of HAMA and MAb-Alt-2. The binding to cells was assessed by flow cytometry.

As shown in Figures 5A (percent positive cells) and 5B (mean fluorescence
15 intensity), HAMA further enhanced the binding of CA125 to human monocytes and dendritic cells. Immune complexes with HAMA increased the percentage of CA125-targeted cells within the monocytes and dendritic cell populations (Figure 5A), but increased the CA125 concentration per cell mainly in dendritic cells (Figure 5B).

20 Example VI

Alt-6 Antibody and Alt-6-PSA Immune Complex Binding to DC at Different Stages of Development and Maturation

DC of different stages of development and maturation were first analyzed by flow cytometry to determine their level of expression of Fcγ receptor. To do this, DC
25 were isolated from PBMC as described above and tested for Fcγ receptor expression with fluorescence labeled antibodies at day 0, after 4 days in culture with GM-CSF/IL-4 and after maturation with TNFα and IFNα (7 days). Binding was determined on CD11c+, HLA-DR+ cells and is expressed in Table II (below) as percentage of positive cells within the gate.

30 As shown below on Table II, DC express Fcγ type I, and type II receptors (CD64 and CD32), and low levels of FcγR III (CD16)

Table II
Distribution of Fc γ Receptors on DC at Different Stages of Maturation

Fc γ Receptor	Days in culture		
	0	4	7
	Positive Cells [%] (gated on DC)		
CD16 (Fc γ RIII)	3 – 15	15 – 40	0.5 – 5
CD32 (Fc γ RII)	89 – 98	70 – 95	40 – 45
CD64 (Fc γ RI)	92 – 99	28 – 60	4 – 10

5

The percent of DC expressing these Fc γ receptors differed depending on their stage of maturation/differentiation. As shown on Table II, the number of DC expressing CD16 was highest after culture for 4 days with GM-CSF/IL-4 and was nearly absent on DC after maturation (*i.e.*, after 7 days in culture with GM-CSF/IL-4).
 10 CD32 and CD64 were found on the majority of DC precursors. CD32 was expressed on 70-95% of immature DC and declined to about 40% on mature DC. In addition, the number of CD64 expressing cells declined as the DC differentiated and matured.

Next, to determine if the anti-PSA monoclonal antibody Alt-6 and Alt-6-PSA immune complexes would bind to DC and if the stage of DC differentiation and
 15 maturation affected binding, a range of concentrations of the fluorescein-labeled Alt-6 as well as Alt-6-PSA-FITC-complexes were added to three different populations of DC: I) freshly isolated myeloid DC precursors (surface phenotype-CD11c+, HLA-DR+, CD14+), II) DC after culture for 4 days in GM-CSF/IL-4 (surface phenotype-CD11c+, HLA-DR+, CD14-, CD86+) and III) DC that had been further matured by
 20 culturing for an additional 3 days with TNF α and IFN α (surface phenotype-CD11c+, HLA-DR+, CD86+, CD40+, CD80+, CD83+) (see Table I above).

To do this, PSA was purchased from Scripps Laboratories (San Diego, CA) and the murine monoclonal anti-PSA antibody Alt-6 (ProstaRex™) was kindly provided by AltaRex Corporation, Edmonton, Alberta, Canada (ATCC No. HB-
 25 12526; American Type Culture Collection, Manassas, VA). Alt-6 is an IgG1 antibody that reacts specifically with an epitope that maps to the region of amino acid residues 137-146 (sequence EPEEFLTPKK) of PSA. PSA and Alt-6 were diluted in cRPMI to concentrations of 5 and 25 μ g/ml, respectively. When mixed at these concentrations, approximate equimolar amounts of PSA and anti-PSA were achieved.

Alt-6 was labeled with Fluorescein-EX (commercially available from Molecular Probes, Eugene, OR) following manufacturers instructions. Equimolar concentrations of PSA were mixed with 1.25 µg/ml, 2.5 µg/ml, 5.0 µg/ml, and 25 µg/ml of Alt-6-FITC and added to freshly isolated DC precursors, to DC that had been cultured for 4 days in the presence of GM-CSF/ IL-4 and to DC that had been matured.

The antibody-PSA composition was incubated for 1 hour at 37°C, washed, pelleted, fixed in 2% paraformaldehyde, and analyzed by flow cytometry. DC were gated in the sideward/forward scatter based on DC preparations stained in parallel with the complete DC marker panel (see Example I). The percentage of cells that reacted with Alt-6 and Alt-6-PSA complexes were calculated based on binding to CD11c+, HLA-DR+ cells. Table III (below) shows percentage of positive cells within the gate.

Table III
PSA-Specific Monoclonal Antibody Alt-6 and Alt-6-PSA Immune Complex Binding to DC at Different Stages of Maturation

		Days in culture		
		0	4	7
	Antibody Concentration	Positive Cells (gated on DC) [%]		
Alt-6-FITC	1.25 µg/ml	0.13	0.68	
	2.5 µg/ml	0.16	1.56	
	5 µg/ml	1.84	9.95	1.19
	25 µg/ml	7.33	28.1	
Alt-6-FITC + PSA	1.25 µg/ml	1.82	2.41	
	2.5 µg/ml	3.91	8.70	
	5 µg/ml	5.38	23.40	1.56
	25 µg/ml	18.00	72.11	

As shown in Table III, at the concentrations tested, Alt-6 bound to a low percentage of freshly isolated DC precursors. The number of cells binding the antibody increased after culture for 4 days in GM-CSF and IL-4. Interestingly, the number of cells binding Alt-6-FITC was significantly higher in the presence of PSA, indicating that the Fc receptors have enhanced binding to immune complexed antibody over the antibody alone, or that immune complexes bind to different and/or more abundant receptors on DC precursors and immature DC. No binding of the Alt-6 or the immune complexes occurred to mature DC.

Example VII

T Lymphocyte Responses to DC armed with PSA or PSA/anti-PSA

5 T lymphocytes were stimulated with DC armed with PSA or a combination of PSA/anti-PSA antibody.

To do this, monocytes were generated from leukaphoresis samples from healthy donors (Biological Specialty Corp., Colmar, PA) and depleted from lineage cells by incubation with anti-CD3, CD19 and CD 16 antibodies, followed by incubation
10 with magnetic bead conjugated anti-mouse Ig and separation on a magnet (Dyna). Negatively selected cells were approximately 70% pure monocytes as characterized by flow cytometry using a broad CD marker panel (see Example I). Monocytes were incubated with IL-4 and GM-CSF (R&D Systems) for 4 days in RPMI1640 + 10% matched human serum to generate immature DC. Again, an aliquot of the cells was
15 stained with a broad CD marker panel to ensure purity and identity of the cells. These cells were then harvested and loaded with antigen combinations (*e.g.*, PSA, the anti-PSA monoclonal antibody and the antibody-PSA combination) for 2 - 8 hours at 37°C, and then matured with IFN- α and TNF- α for three days. Dendritic cell were checked again via flow cytometry for an array of CD markers to ensure proper maturation of
20 the cells.

Specifically, the immature DCs were loaded with PSA (25 μ g/mL), Alt-6 (5 μ g/mL) and PSA + Alt-6 (25 μ g/mL of PSA; 5 μ g/mL of Alt-6). These immature DCs were added to T cells that were generated from the same monocytes as the DCs via negative selection (*i.e.*, autologous T cells), using a magnetic T cell isolation kit
25 (commercially available from Dynal). Briefly, to isolate T cells, CD3+ T lymphocytes were isolated from thawed PBMC (see Example I) by negative selection (using magnetic beads commercially available from Dynal, Lake Success, NY). Briefly, the cells were incubated on ice for 30 min with a mixture of antibodies to CD14, CD16, CD56 and HLA Class II DR/DP. Excess antibodies were removed by washing with
30 PBS/0.1% BSA. The cells were incubated for 30 min. at room temperature with immunomagnetic beads coated with an anti-mouse IgG antibody (Dyna). The cells were placed against a magnet and the T lymphocytes, which did not bind the magnet

(i.e., did not express CD14, CD16, CD56, and HLA class II DR/DP) were isolated from the supernatant.

T cells and DCs were incubated for 7 days (primary stimulation), re-stimulated with loaded and matured DCs and incubated for another 7 days. For stimulation, T lymphocytes were plated in twenty-four well plates at a concentration of 1×10^6 cells/well and to which were added 5×10^4 DC that were antigen naive or that had been exposed to PSA, the anti-PSA monoclonal antibody or the combination of PSA and the monoclonal antibody. An aliquot of the cells was taken 24 hour later and prepared for intracellular cytokine staining (Day 15; primary stimulation), whereas the remaining cells were incubated for another 7 days (secondary stimulation) and prepared for intracellular cytokine staining on Day 22. Prior to adding the second or third DC preparation, an aliquot of the cell supernatant was taken for testing in an IFN- γ ELISA (Pharmingen DouSet).

For the intracellular cytokine staining, cells were incubated with Golgi Plug (R&D Systems) 2 hours after DC addition and incubated for another 16-18 h. Cells were stained with anti-CD3-FITC and anti-CD8-Cy-Chrome for 30 min. on ice, washed, permeabilized, and stained with anti-IFN- γ -PE for 30 min. on ice. Cells were washed, fixed and analyzed by flow cytometry (FACS Calibur, Becton Dickinson).

T cell responses were measured as numbers of CD4+ and CD8+ T cells producing intracellular IFN γ . To do this, flow cytometry was used. Briefly, Brefeldin A (10 μ g/ml) (commercially available from Pharmingen, San Diego, CA) or Golgi Plug (commercially available from R&D Systems) was added to the T cell cultures 2 hours after restimulation with antigen armed DC. After an additional 16-18 hours of culture, cells were stained with anti-CD3-FITC and anti-CD8-Cytochrome for 30 min. on ice, washed, permeabilized (e.g., by incubating in a perm/fix solution (Pharmingen) for 20 min. on ice), and stained with anti-IFN- γ -PE for 30 min. on ice in staining buffer (PBS with 1% human AB serum (i.e., human sera from a person with type AB blood) (antibodies commercially available from Becton Dickinson, San Jose, CA) added. The cells were washed, resuspended in staining buffer containing 2% paraformaldehyde and analyzed by flow cytometry (FACS Calibur, Becton Dickinson).

In this experiment, mature "armed" or "un-armed" DC (i.e., matured with cytokines alone) were co-cultured with autologous T cells, restimulated with armed or

un-armed DC, and the number of CD4+ and CD8+ cells producing IFN γ was determined. The results of a representative experiment are shown in Figure 6.

As shown in Figure 6, little to no difference in number of IFN γ producing CD4+ or CD8+ T cells were found in co-cultures with DC that were not exposed to antigen (negative control) or T cells cultured with DC that had been exposed to the monoclonal antibody (*i.e.*, α -PSA as primary stimulated) and were then restimulated with armed or un-armed DC. In all combinations of primary stimulation and restimulation, PSA armed DC stimulated CD4+ T cell responses were consistently greater than CD8+ T cell responses. Notably, strong CD8+ T cell responses were observed on restimulation with immune complex armed DC (*i.e.*, where restimulation was with the complex and primary stimulation was with the complex of PSA/ α -PSA). When T cells were cultured with antigen-antibody armed DC (*i.e.*, primary stimulation is PSA/ α -PSA) and restimulated with PSA armed DC, CD4+ T cell responses were substantially greater than CD8+ responses.

On the other hand, consistent CD4+ and CD8+ IFN γ responses were only generated in T cells exposed to and restimulated by antigen-antibody armed DC (*i.e.*, where both primary stimulation and restimulation was PSA/ α -PSA). Since IFN γ T cell responses were not generated to the Alt-6 antibody (*i.e.*, α -PSA alone as primary stimulation or restimulation), it is expected that the response to the complex is directed at the PSA. The increase in CD8+ T cell responses to PSA presented in combination with the antibody compared to the responses with free PSA alone indicate that the immune complex enhances antigen processing, in particular, through the HLA Class I pathways.

Example VIII

T Lymphocyte Responses to DC Armed With CA125 or CA125/ α CA125

Complex

After identifying broad ranges of functional CA125 and MAb- Alt-2 concentrations for T cell stimulation in small checkerboard assay for IFN- γ release into the supernatant, intracellular cytokine staining assays were performed using 50, 500 and 5000 U/mL of CA125 in the absence and presence of 2.5 μ g of MAb-Alt-2. Matured DC cells and T cells were incubated for 7 days and then re-stimulated with

loaded and matured DCs. Seven days after stimulation with loaded DCs (Figure 7, round 1), and after the restimulation (Figure 7, round 2), an aliquot of the cell supernatant was taken and tested in an IFN- γ ELISA (Pharmingen DouSet).

As a positive control, PMA + Ionomycin was used for stimulation of the T cells in culture. DCs loaded in medium only were used to determine the background of the assay.

As shown on Figure 7, stimulation with CA125 alone did not result in substantial IFN- γ release, detected by IFN- γ ELISA of the cell supernatants (Figure 7).

For intracellular staining studies, immature DCs were loaded with CA125 (50, 500, 5000 U/mL), Alt-2 (2.5 μ g/mL) and CA125 + Alt-2 (50, 500, 5000 U/mL of CA125; 2.5 μ g/ml of Alt-2) and matured. T cells and DCs were incubated for 7 days, and re-stimulated with loaded and matured DCs. An aliquot of the cells was taken 24 hours later and prepared for intracellular cytokine staining (Day 15; Figure 8A), whereas the remaining cells were incubated for another 7 days. Those cells were stimulated with another batch of loaded and matured DCs and prepared for intracellular cytokine staining on Day 22 (Figure 8B). For the intracellular cytokine staining, cells were incubated with Golgi Plug (R&D Systems) 2 hours after DC addition and incubated for another 16-18 hours. Cells were stained with anti-CD3-FITC and anti-CD8-Cy-Chrome for 30 min. on ice, washed, permeabilized, and stained with anti-IFN- γ -PE for 30 min. on ice. Cells were washed, fixed and analyzed by flow cytometry (FACS Calibur, Becton Dickinson).

As shown on Figures 7, 8A, and 8B, responses to CA125 could be detected only after two stimulation rounds and at the highest concentration tested. As shown in Figures 8A and 8B, antigen alone mainly stimulated CD4 responses as shown by the intracellular staining results. As shown on Figure 7, substantially increased IFN- γ release was observed in responses to CA125 presented in a complex with MAb-Alt-2 by human DC. IFN- γ release into the cell supernatant, detected by IFN- γ ELISA, as well as intracellular cytokine production (ICC) could be detected already after one stimulation round and was further increased after the second round of stimulation (Figures 7 and 8B, respectively). CA125 concentrations as low as 50 U/mL were able to stimulate T cells, with an optimum of 500 U/mL at two stimulation rounds (Figures 7, 8A, and 8B).

Of particular note is the finding that the CA125-MAb Alt-2 immune complexes induced initially strong CD4 responses (Figure 8A) and with additional stimulation also strong CD8 responses (Figure 8B). These observations indicate that CA125 can be presented on MHC class I and II if presented in the form of an immune complex, but only on MHC class II molecules, if taken up alone, as expected for extracellular antigens. The receptor responsible for the uptake of the antigen or antibody-antigen complex may influence the route for processing of the internalized protein. Antigen-antibody complexes may have increased leakage into the cytosol and therefore better chance of being processed by the proteasomes, the processing machinery that transports peptides onto MHC class I molecules via the invariant chain.

Example IX

PSA/anti-PSA Complex-Armed DC Generate HLA-A*0201 Peptide-Specific T

Lymphocyte Responses

The ability of PSA/anti-PSA immune complexes and PSA armed DC to generate T lymphocyte responses to two PSA peptides that are known to be restricted by the HLA-A*0201 allele was next compared. To do this, two HLA-A2 specific PSA peptides (pep1, FLTPKKLQCV; pep2, KLQCVDLHV) and an HIV-1 peptide (SYNTVAVL) were synthesized by the Biopolymer Laboratory, University of Maryland, Baltimore, MD, diluted in cRPMI, added to the DC preparations at concentrations of 5 µg/ml, and incubated for approximately 1 hour.

DC were prepared as described in Example I and exposed to PSA or PSA/anti-PSA complex after 4 days of culture in GM-CSF/IL-4. Following maturation with CD40L or TNFα and IFNα, the armed DC were cultured with autologous CD3+ selected T lymphocytes for 7 days. The T cells were next harvested, newly armed DC added to the cell culture, and the cells cultured for an additional 7 days in media supplemented with IL-2 (10 U/ml) and IL-7 (5 ng/ml) (see Example III).

At day 14, the T cells were harvested and restimulated with matured DC that were pulsed with the two PSA-derived peptides and analyzed for IFNγ release.

Results of a representative experiment (1 of 3) are shown in Figure 9. In T cells cultured with PSA-armed DC for 2 weeks, low levels of CD4+ responses were detected upon restimulation with the PSA-derived peptides. Peptide 2

(KLQCVDLHV) also induced small CD8+ responses when the primary stimulation was PSA alone. Consistent with the previous results described in Example III, restimulation of T cells with PSA-armed DC (where the primary stimulation was PSA) resulted in CD4+ T cell responses, and low levels of responding CD8+ T cells.

- 5 Restimulation with the PSA/anti-PSA complex (where the primary stimulation was PSA) showed similar activation of CD4+ as well as CD8+ INF γ responses.

As the lower half of Figure 9 shows, T cells cultured with PSA/anti-PSA armed DC for two weeks were able to respond to both PSA-derived peptides. Peptide-restricted responses were approximately twice as strong in T cells cultured with
10 PSA/anti-PSA armed DC before restimulation as compared to the responses to peptide by PSA-armed DC (*i.e.*, T cells whose primary stimulation was PSA alone).

Note that T cells propagated in the presence of PSA-armed DC were able to respond weakly to peptide 2 (KLQCVDLHV), but the CD8+ T cells did not release INF γ upon restimulation with PSA-armed DC. This results suggests that this peptide
15 may be presented by HLA Class II molecules as well as by Class I, but that the generation of T cells specific for this peptide are not effectively generated by DC loaded with PSA. No responses were found when the T cells that had been cultured with immune complex were stimulated with mature DC that had been pulsed with an HLA-A*0201 restricted HIV-1 gag peptide (data not shown).

20

Example X

T cell responses to DC armed with PSA or PSA-m

DC express receptors that bind mannose and related carbohydrates. Accordingly, experiments were conducted to compare the T cell responses to DC that
25 had been armed with PSA or PSA that had been conjugated to mannose. To do this, PSA was purchased from Scripps Laboratories (San Diego, CA). PSA was mannosylated as follows: 100 μ g of PSA was combined with 100 μ g α -D-mannopyranosylphenylisothiocyanate (α -D-M) and 2 μ l N-methylmorpholine in 460 μ l of PBS and stirred overnight at room temperature. Excess α -D-M was hydrolyzed by
30 the addition of 100 μ l of 1M Trizma-base (pH 9.5). Unconjugated mannose residues were removed by dialysis against PBS and stored at 4°C.

The T cells were exposed through two weekly rounds of stimulation to DC armed with PSA or PSA-m and CD4+ and CD8+ IFN γ responses measured after re-exposure to armed DC. To do this, as described in Example III, T cells were exposed to DC armed with PSA or mannosylated-PSA (PSA-M) and cultured. At day 14, T cells were restimulated with unarmed or antigen armed DC and numbers of CD4+ and CD8+ T cells producing IFN γ determined by flow cytometry. The results are shown in Table IV.

Table IV
Comparison of T Cell Responses to Dendritic Cells Armed With
PSA or Mannosylated PSA

Primary stimulation	Restimulation	IFN γ + cells/ 10^6	
		CD4+	CD8+
O	PSA	33	42
PSA	O	109	41
PSA	PSA	438	88
PSA	PSA-M	566	92
O	PSA-M	80	61
PSA-M	O	111	82
PSA-M	PSA-M	894	122
PSA-M	PSA	504	113

As show in Table IV, in three separate experiments, CD4+ T cell responses predominated within the activated cell population and were consistently higher when DC were loaded with PSA-m compared to responses to PSA armed DC. Small to modest increases (over controls) in number of activated CD8+ T cells were observed. However, the CD8+ T cell response to PSA-m was far below responses seen with Alt-6-PSA immune complexes (see Figure 6).

Example XI

Clinical Studies

Patients suffering from recurring ovarian cancer were injected with 2 mg monoclonal antibody Alt2 per day, with a total of 1 to 10 such treatments and followed for disease progression and survival. Alt2 is a murine monoclonal IgG1 antibody to CA125. The antibody has a high affinity ($1 \times 10^{10} \text{ M}^{-1}$) and was modified, such as by photoactivation (partial reduction of disulfide bonds, see U.S. Patent No. 6,086,873).

All patients were tested for HAMA and CA125 before and after each injection by ELISA (HAMA, commercially available from Medac, Germany; CA125, commercially available from Centocor, USA). Seventy-five patients were tested for anti-idiotypic antibodies (Ab₂) to Alt2 by ELISA (commercially available from AltaRex Corp., USA) and anti-CA125 antibodies by ELISA (AltaRex; see also Schultes *et al.*, Cancer Immunol. Immunother. 46: 201 (1998)). For 17 patients, peripheral blood mononuclear cells (PBMC) were available before and after injection.

To determine how quickly the injected Alt2 antibody could form immune complexes with free CA125, CA125 was captured from serum samples (that were obtained at various time points after MAb Alt-2 injection) with the anti-CA125 antibody MAb-B27.1, which recognizes an epitope distinct from MAb Alt-2. After washing, tubes were incubated with ¹²⁵I-MAb-Alt-2 or ¹²⁵I-MAb OC125. This procedure allows for detection of CA125 bound MAb Alt-2 in the serum, indicated by decreased tracer binding of ¹²⁵I-MAb Alt-2 in comparison to preinjection samples as well as decreased binding in comparison to ¹²⁵I-MAb OC125. As shown in Figures 10A and 10B, MAb-Alt-2 was found to form complexes with CA125 within 30 minutes of injection of the antibody. These complexes cleared very slowly from circulation at the first MAb Alt-2 injection (see right half of Figure 10B). The results show that MAb Alt-2 can bind to CA125 in circulation and form long circulating immune complexes. Consequently there is an opportunity of such complexes to be taken up by the immune system and undergo processing and presentation to T cells.

In addition, PBMC of the antibody-injected patients were analyzed for T cell proliferation to CA125 in a standard ³H-thymidine uptake assay without *in vitro* sensitization (for assay methods see, *e.g.*, Current Protocols in Immunology, ed. John E. Coligan, John Wiley & Sons, Inc. 1993; Current Protocols in Molecular Biology, eds. Ausubel *et al.*, John Wiley & Sons, Inc. 2000). The results are shown in Figures 11A-13B.

Induction of humoral (Pearson $r=0.8335$, $p<0.001$) and cellular ($p=0.037$) anti-CA125 responses showed a correlation with the amount of circulating CA125 antigen present at the time of Alt2 injection (Figures 11A-11C). Neither B nor T cell responses specific for CA125 were detected in the pre-injection samples. Analysis of the patients' anti-CA125 antibodies revealed that they were directed against multiple

epitopes of CA125 (Figure 12). This analysis was done by inhibiting human α -CA125 antibody by various α -CA125 monoclonal antibodies that specifically bound to distinct epitopes on CA125.

In addition, survival from the time of first antibody injection correlated with the generation of anti-CA125 antibodies (median survival 22.9 v. 13.5 months, $p=0.0089$; Figure 13A) and generation of CA125-specific T cells (84 v. 13.2 months, $p=0.0202$; Figure 13B) after Alt2 injection for anti-CA125 responders v. non-responders. These results demonstrate the following. The levels of circulating CA125 at time of Alt2 injection showed influence on the frequency and amount of immune responses induced to CA125 after injection of the antibody. Patients' anti-CA125 antibodies were found to be multi-epitopic (See Figure 12). As Figures 13A and 13B show, survival after the first injection of Alt2 (plotted in Kaplan-Meier curves) was significantly longer in patients with CA125-specific antibodies (increase in titer > 3 times pre-injection value), and in patients with CA125-specific T cells ($SI>1.5$) (log-rank test, $p<0.01$ and $p<0.05$ respectively).

Example XII

Effect of complex formation on antigen presentation

CA125 was purified from tissue culture supernatants of NIH:OVCAR-3 cells (commercially available from AltaRex Corp.) and PSA was purified from human seminal plasma (commercially available from Scripps, La Jolla, CA) using standard procedures. Photoactivated Alt2 antibody was as described previously (see Example VII). The anti-PSA antibody, Alt6 (commercially available from AltaRex Corp.), is a mouse IgG1 that binds to the region of amino acids 135 to 150 of PSA. HAMA was as described previously (see Example VI). Human dendritic cells were prepared from buffy coats by Ficoll-Hypaque and negative selection with anti-CD3, CD16 and CD19, followed by anti-mouse-IgG magnetics beads (Dyna). Cells were cultured in 1000 U/ml GM-CSF and 1000 U/ml IL-4 for 4 days.

Murine macrophages were isolated from the peritoneal cavity of Balb/c mice. Specific B cells were isolated from immunized mice by panning on antibody-coated petri dishes. Dendritic cells were loaded with antigen, antibody, or antigen-antibody complex at day 4 and matured with 10 ng/ml TNF- α and 50 U/ml IFN- α 4 hours later.

Two stimulation rounds were performed before analyzing the cells for intracellular IFN- γ staining for either CD4 and CD8 T cells or for the release of IFN- γ into the culture supernatant.

The results are shown in Figures 14A-14B. These results show that antigen
5 complexed with specific antibody can be preferentially presented by professional APC
such as macrophages (Figure 14A) and B cells (Figure 14B). Results from the
antigen-antibody system with PSA and CA125 in dendritic cells support an enhanced
presentation of the extracellular antigen on MHC class I when offered as an immune
complex (see Figures 6, 8A, and 8B). Also, these results further confirmed the results
10 shown in Table IV (above); namely that while mouse IgG1 alone binds weakly to
dendritic cells (Figure 2), the binding is enhanced by binding of specific antigen, and
substantially enhanced in the presence of HAMA (Figures 3A-5B). Finally, these
results demonstrate that dendritic cells present immune complexes better than non-
complexed antigen (Figures 6, 8A, and 8B) and, upon repeated stimulation, the
15 immune complexes shifted the immune response from a helper (CD4+) to a cytolytic
(CD8+) T cell response (Figures 6 and 8B), indicating presentation of antigen-derived
peptides on both MHC class I and class II.

20

Example XIII

Ex vivo therapeutic treatment

A human-PBL-SCID/BG mouse model is used generally as described in
Schultes *et al.*, Hybridoma 18: 47-55 (1999). Human ovarian cancer cells
NIH:OVCAR-NU-3 are passaged through nude mice and maintained at 37°C and 5%
25 CO₂ using RPMI 1640 medium supplemented with 2 mM L-glutamine and 10% fetal
bovine serum (Life-Technologies, Gaithersburg, MD). SCID/BG mice are obtained from
Taconic (Germantown, NY). Tumors are developed in the SCID/BG mice by
subcutaneous injection of 4 x 10⁶ NIH:OVCAR-NU-3 tumor cells and three weeks
incubation. Dendritic cells are loaded with CA125 antigen or with CA125 antigen and
30 Alt2 antibody as described in Example III, with or without HAMA. The combination
is then administered to the mouse either intraperitoneally or intravenously. This
treatment is repeated every 2 to 3 weeks. Tumor burden and days of survival are
monitored. It is expected that the dendritic cells loaded with the antigen-antibody

complex have a greater anti-tumor effect than the dendritic cells loaded with antigen alone, and that the greatest effect is observed when the dendritic cells loaded with the antigen-antibody-HAMA complex are administered.

5

Example XIV

In vivo Efficacy of an Antigen-Specific

Monoclonal Antibody in Murine Animal Model

The efficacy of the Alt1, Alt2 and Alt2 monoclonal antibodies (MAb) *in vivo* and the role of antibody-antigen complexes in the induction of an immune response and anti-tumor responses were studied in murine animal models. The immunization of mice with Alt1, Alt2 and Alt6 MAb was studied to determine whether Alt1, Alt2 and Alt6 can (a) induce a specific immunity against the specific antigen, MUC1, CA125 or PSA, respectively, (b) protect the mice against subsequent tumor challenge; and (c) eradicate established tumors and/or increase survival.

These experiments were performed using DBA and Balb/c and human PBL-SCID/bg mice which allowed one to choose the best animal model for future experiments. Five groups of mice were immunized respectively with MAb, control MAb, and MAb/antigen complexes. Antigen and PBS controls were studied. The immunization and tumor induction procedures were identical to the ones used for previous studies. Survival curves were plotted using the Meir Kaplan Algorithm. Comparison of responses between various groups were analyzed using standard statistical procedures.

Specifically, to do these studies, the treatment groups described in Table V were set up using SCID/bg mice:

25

Table V

Group	Mice Number	Treatment
1	9	phosphate buffered saline (PBS) i.v.
2	9	MOPC-21 i.v.
3	9	Alt-6 i.v.
4	9	Alt-6 plus PSA i.v.
5	8	PSA i.v.
6	8	Alt-6 s.c
7	8	MOPC-21 s.c.

i.v. (intravenous) injection: 50 µg of antibody and/or 10 µg of PSA

i.p. (intraperitoneal) injection: 100 µg of antibody and/or 20 µg PSA

s.c. (subcutaneous) injection: 50 µg of antibody

Groups 1-5 received the first two injections intraperitoneally., and the next four intravenously

- Groups 6-7 received the first two injection intraperitoneally, and the next four subcutaneously with the adjuvant Quil A.

The treatment schedule was as follows in Table VI:

Table VI

Day	procedure	comments
1	PBL (1×10^7 human PBL/mouse) i.v. plus immunization, i.p.	PBL (peripheral blood leukocytes) from one HLA-A2+ donor
8	immunization, i.p. Dose 2	
12	Bleeding for hlgG testing	3×10^6 /mouse with 75% Matrigel
18	LnCap (tumor) inoculation s.c.	
21	immunization i.v./s.c. Dose 3	
29	immunization i.v./s.c. Dose 4	
35	immunization i.v./s.c. Dose 5	
42	immunization i.v./s.c. Dose 6	
48	Terminate mice/weigh tumor	When biggest tumor reached 10x19mm

- On Day 22, human IgG levels were measured (as mg/ml). As can be seen on Figure 15, those mice injected with PBS only (*i.e.*, Group 1) had the highest level of human IgG antibodies.

To measure successful reconstitution of human PBLs in the mice, serum human IgG was measured. These results are shown on Table VII.

15

Table VII

Group	Number of mice	Number of mice with greater than 0.1 mg/ml hIgG	Percentage of mice with greater than 0.1 mg/ml hIgG
PBS i.v.	9	5	56
MOPC-21 i.v.	9	7	78
Alt-6 i.v.	9	0	0
Alt-6 + PSA i.v.	9	2	22
PSA i.v.	8	6	75
Alt-6 s.c	8	4	50
MOPC-21 s.c.	8	3	38

All off the mice in all groups grew tumor (*i.e.*, from the LnCap inoculation).

These tumors were palpable 17 days after inoculation (*i.e.*, Day 35). The tumors were measured twice a week.

As shown in Figure 16, the mouse group injected with Alt-6 plus PSA i.v. demonstrated the best tumor suppression (Alt-6 plus PSA i.v. versus PSA iv; $P=0.0477$). The Alt-6 i.v. group also showed tumor suppression (as measured by tumor volume)..

5 These results demonstrated that best anti-tumor effects were achieved in mice treated with the antibody-antigen complexes.

The humoral immune response was monitored by measuring the serum levels of Ab2 and Ab3 in ELISAs.

10 The cellular immune response was monitored according to routine laboratory procedures by measuring lymphocyte proliferation.

Example XV

Histopathological and Toxicological Studies

The tissue antigen specificity of ALt1 and Alt2 was examined by histopathological reactivity with both normal and tumor human tissues. The degree of heterogeneity in reactivity was recorded. This study was conducted by a commercial organization (Impath Inc.) under GLP conditions.

Acute and subacute toxicity of naked Alt1 and Alt2 was conducted in two species (rat and rabbits) by the division of the animal services at the University of Alberta. There was toxicity observed in acute or subacute studies.

20

Example XVI

Phase I Clinical Trial

Because there was data available on the "safety" of murine antibodies administered to humans, it was not expected that side effects were a dose limiting problem. However, standard criteria such as major organ toxicity and patient symptoms were followed utilizing GCP. As antibody doses did not have to be pushed to toxicity (the maximally tolerated dose) the major outcome became defining the most effective dose of antibody that elicited the desired defined immune response.

30 The patient population to be studied needed to be immune competent and have the target disease. A group of patients with MUC1 expressing tumor were enrolled in a three-dose Phase I trial with Alt-1

Based on studies with other immune therapies it was expected that the effective dose was in the 1-4 mg dose. Doses of 1, 2, and 4 mg were studied in the stated patient population. Toxicity criteria were monitored along with the immune response (primary endpoint). Evidence of therapeutic activity was detected by monitoring patient MUC1 levels (secondary endpoint). Six patients per dose level were treated. The 2 mg dose was most effective in inducing HAMA, Ab2, anti-MUC1 antibodies and MUC1-specific T cells, and showed the highest incidence of MUC1 serum level stabilization or decrease.

10

EQUIVALENTS

Those skilled in the art will recognize, or be able to ascertain, using no more than routine experimentation, numerous equivalents to the specific embodiments described specifically herein. Such equivalents are intended to be encompassed in the scope of the following claims.

We claim:

1. A method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising an antigen associated with the disease and a dendritic cell binding agent specific for the antigen, wherein the antigen is complexed to the binding agent and wherein the patient administered the composition receives a therapeutic benefit.
2. The method of claim 1, wherein the patient is human.
3. The method of claim 1, wherein a CD8+ IFN- γ producing T cell is activated to induce a CTL immune response in the patient administered the composition.
4. The method of claim 1, wherein a CD4+ IFN- γ producing T cell is activated to induce a helper T cell immune response in the patient administered with the composition.
5. The method of claim 1, wherein a humoral immune response is activated in the patient administered the composition.
6. The method of claim 1, wherein the dendritic cell binding agent specifically binds to the antigen and binds to an Fc γ Type I (CD64) receptor on a dendritic cell in the patient administered the composition.
7. The method of claim 1, wherein the dendritic cell binding agent specifically binds to the antigen and binds to an Fc γ Type II (CD32) receptor on a dendritic cell in the patient administered the composition.
8. The method of claim 1, wherein the dendritic cell binding agent specifically binds to the antigen and binds to an Fc γ Type II CD16 (Fc γ RIII) receptor on a dendritic cell in the patient administered with the composition.
9. The method of claim 1, wherein the dendritic cell binding agent is an antibody.
10. The method of claim 3, wherein the dendritic cell binding agent is a xenotypic antibody to the patient.
11. The method of claim 10, wherein the xenotypic antibody elicits a human anti-xenotypic antibody response in the patient.

12. The method of claim 11, wherein host anti-xenotypic antibodies (HAXA) are present in the patient's blood prior to administering the composition.

13. The method of claim 11, wherein the xenotypic antibody is a monoclonal antibody.

5 14. The method of claim 14, wherein the monoclonal antibody is a murine monoclonal antibody.

15. The method of claim 15, wherein the murine monoclonal antibody is selected from the group consisting of Alt-1, Alt-2, Alt3, Alt-4, Alt-5; and Alt-6.

10 16. The method of claim 3, wherein the composition further comprises human anti-xenotypic antibodies (HAXA).

17. The method of claim 1, wherein the antigen is a tumor-associated antigen.

18. The method of claim 1, wherein the antigen is from a pathogen.

15 19. A method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising a host anti-xenotypic antibody and a xenotypic antibody specific for the antigen associated with the disease, wherein the patient administered the composition receives a therapeutic benefit.

20. The method of claim 19, wherein the antigen is present in the patient.

21. The method of claim 19, wherein the patient is human.

20 22. The method of claim 19, wherein a CD8+ IFN- γ producing T cell is activated to induce a CTL immune response in the patient administered the composition.

25 23. The method of claim 19, wherein a CD4+ IFN- γ producing T cell is activated to induce a helper T cell immune response in the patient administered the composition.

24. The method of claim 19, wherein a humoral immune response is activated in the patient administered the composition.

30 25. The method of claim 19, wherein the xenotypic antibody specifically binds to the antigen and binds to an Fc γ Type I (CD64) receptor on a dendritic cell in the patient administered the composition.

26. The method of claim 19, wherein the xenotypic antibody specifically binds to the antigen and binds to an Fcγ Type II (CD32) receptor on a dendritic cell in the patient administered the composition.

27. The method of claim 19, wherein the xenotypic antibody specifically binds to the antigen and binds to an Fcγ Type II CD16 (FcγRIII) receptor on a dendritic cell in the patient administered with the composition.

28. The method of claim 19, wherein the xenotypic antibody is a monoclonal antibody.

29. The method of claim 28, wherein the monoclonal antibody is a murine monoclonal antibody.

30. The method of claim 29, wherein the murine monoclonal antibody is selected from the group consisting of Alt-1, Alt-2, Alt3, Alt-4, Alt-5; and Alt-6.

31. The method of claim 1, wherein the antigen is a tumor-associated antigen.

32. The method of claim 1, wherein the antigen is from a pathogen.

33. A therapeutic composition comprising a purified dendritic cell binding agent that is specific for an antigen associated with a disease and the antigen associated with the disease.

34. The composition of claim 33, wherein binding of the dendritic cell binding agent to a receptor on a dendritic cell blocks binding of a natural ligand to the receptor.

35. The composition of claim 33, wherein administration of the composition to a patient suffering from the disease provides the patient a therapeutic benefit.

36. The composition of claim 33, wherein the patient is human.

37. The composition of claim 33, wherein the dendritic cell binding agent is an antibody.

38. A therapeutic composition comprising a host anti-xenotypic antibody and a xenotypic antibody specific for the antigen associated with the disease.

39. The composition of claim 38, wherein administration of the composition to a patient suffering from the disease provides the patient a therapeutic benefit.

40. The composition of claim 38, wherein the patient is human.




FIG. 1A

FIG. 1B

2/22




FIG. 2




Figure 3B




Figure 3A

4/22

COMPLEXATION WITH SPECIFIC ANTIGEN OR HAMA
INCREASES ANTIBODY-BINDING TO DC
(FACScan)




FIG. 4A




Figure 4C




Figure 4B

6/22




FIG. 5A

7/22




FIG. 5B

8/22




FIG. 6




FIG. 7

10/22




FIG. 8A

11/22




FIG. 8B




FIG. 9

13/22




FIG. 10A

14/22




FIG. 10B




FIG. 11A

15/22




FIG. 11B




FIG. 11C

16/22




FIG. 12

17/22




FIG. 13A

18/22




FIG. 13B

19/22




FIG. 14A

20/22




FIG. 14B

21/22





FIG. 15



Alt-6 +PSA VS. PSA: $p < 0.05$

FIG. 16

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau



(43) International Publication Date
15 November 2001 (15.11.2001)

PCT

(10) International Publication Number
WO 01/085204 A3

- (51) International Patent Classification⁷: **A61K 39/00**, 39/385, 39/395, A61P 31/00, 35/00, 37/00
- (21) International Application Number: PCT/IB01/01331
- (22) International Filing Date: 11 May 2001 (11.05.2001)
- (25) Filing Language: English
- (26) Publication Language: English
- (30) Priority Data:
60/203,635 11 May 2000 (11.05.2000) US
60/253,671 28 November 2000 (28.11.2000) US
60/253,956 28 November 2000 (28.11.2000) US
- (71) Applicant: **ALTAREX CORP.** [CA/CA]; University of Alberta, 1123 Dentistry Pharmacy Building, Edmonton, Alberta T6G 2N8 (CA).
- (72) Inventors: **SCHULTES, Birgit**; 12 Monadnock Road, Arlington, MA 02476 (US). **NOUJAIM, Antoine**; 58 Wilkin Road, Edmonton, Alberta T6M 3K4 (CA).
- (74) Agent: **CÔTÉ, France**; Swabey Ogilvy Renault, Suite 1600, 1981 McGill College Avenue, Montréal, Québec H3A 2Y3 (CA).
- (81) Designated States (*national*): AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW.
- (84) Designated States (*regional*): ARIPO patent (GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG).
- Published:
— with international search report
— before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments
- (88) Date of publication of the international search report:
22 August 2002
- For two-letter codes and other abbreviations, refer to the "Guidance Notes on Codes and Abbreviations" appearing at the beginning of each regular issue of the PCT Gazette.

(54) Title: THERAPEUTIC METHOD AND COMPOSITION UTILIZING ANTIGEN-ANTIBODY COMPLEXATION AND PRESENTATION BY DENDRITIC CELLS

(57) Abstract: Disclosed are methods and compositions for use in immunotherapy. These methods and compositions are particularly useful for exploiting dendritic cells to present an antigen to a patient, particularly where the patient has a disease associated with the antigen. The invention provides methods for treating a patient having a disease associated with an antigen. The methods according to the invention comprise combining *ex vivo* an antigen and an antigen-presenting cell binding agent specific for the antigen, and administering the composition to a patient suffering from a disease associated with the antigen, wherein the patient receives a therapeutic benefit.

WO 01/085204 A3

INTERNATIONAL SEARCH REPORT

International Application No
PCT/IB 01/01331

A. CLASSIFICATION OF SUBJECT MATTER IPC 7 A61K39/00 A61K39/385 A61K39/395 A61P31/00 A61P35/00 A61P37/00		
According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) IPC 7 C07K C12N A61K		
Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched		
Electronic data base consulted during the international search (name of data base and, where practical, search terms used) BIOSIS, EMBASE, CHEM ABS Data, WPI Data, PAJ, EPO-Internal, SEQUENCE SEARCH		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 99 65517 A (ALTAREX CORP.) 23 December 1999 (1999-12-23) examples 1,6	1-40
X	M. COCCIA ET AL.: "High titer, prostate specific antigen-specific human IgG production by hu-PBL-SCID mice immunized with antigen-mouse IgG2a complex-pulsed autologous dendritic cells." THE JOURNAL OF IMMUNOLOGY, vol. 161, no. 10, 15 November 1998 (1998-11-15), pages 5772-5780, XP002202308 Baltimore, MD, USA the whole document	1-18, 33-37
-/--		
<input checked="" type="checkbox"/> Further documents are listed in the continuation of box C. <input checked="" type="checkbox"/> Patent family members are listed in annex.		
* Special categories of cited documents : *A* document defining the general state of the art which is not considered to be of particular relevance *E* earlier document but published on or after the international filing date *L* document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) *O* document referring to an oral disclosure, use, exhibition or other means *P* document published prior to the international filing date but later than the priority date claimed *T* later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention *X* document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone *Y* document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art. *&* document member of the same patent family		
Date of the actual completion of the international search		Date of mailing of the international search report
18 June 2002		01/07/2002
Name and mailing address of the ISA European Patent Office, P.B. 5818 Patentlaan 2 NL - 2280 HV Rijswijk Tel. (+31-70) 340-2040, Tx. 31 651 epo nl, Fax: (+31-70) 340-3016		Authorized officer
		Noo1j, F

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 01/01331

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	B. SCHULTES ET AL.: "Induction of CA125-specific B and T cell responses in MAb-B43.13 injected patients depends on complex formation of the MAb with circulating antigen in vivo." THE FASEB JOURNAL, vol. 14, no. 6, 20 April 2000 (2000-04-20), page A1003 XP002202309 Bethesda, MD, USA abstract 53.24 ---	1-18, 33-37
X	DE 195 34 630 A (MAX-DELBRÜCK CENTRUM FÜR MOLEKULARE MEDIZIN) 20 March 1997 (1997-03-20) claim 14 ---	1,2,9, 10,17,18
A	WO 99 65523 A (ALTAREX CORP.) 23 December 1999 (1999-12-23) the whole document ---	1-40
P,X	B. SCHULTES ET AL.: "Antibody-antigen immune complexes allow for efficient MHC class I and II-restricted antigen presentation and maturation of dendritic cells: a novel strategy for cancer immunotherapy." PROCEEDINGS OF THE AMERICAN ASSOCIATION FOR CANCER RESEARCH, vol. 42, March 2001 (2001-03), page 276 XP002202311 USA abstract #1486 -----	1-40

INTERNATIONAL SEARCH REPORT

International application No.
PCT/IB 01/01331

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☒ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

Although claims 1-32 are directed to a method of treatment of the human/animal body, the search has been carried out and based on the alleged effects of the compound/composition.
2. ☐ Claims Nos.:
because they relate to parts of the International Application that do not comply with the prescribed requirements to such an extent that no meaningful International Search can be carried out, specifically:
3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this International application, as follows:

see additional sheet

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.
2. ☒ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.
3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:
4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

This International Searching Authority found multiple (groups of) inventions in this international application, as follows:

1. Claims: 1-18,33-37

Method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from the disease a composition comprising an antigen associated with the disease and a dendritic cell binding agent specific for the antigen, wherein the antigen is complexed to the binding agent and wherein the patient administered the composition receives a therapeutic benefit. Also said (therapeutic) composition.

2. Claims: 19-32,38-40

A method for treating a patient suffering from a disease associated with an antigen, comprising administering to the patient suffering from a disease a composition comprising a host anti-xenotypic antibody and a xenotypic antibody specific for the antigen associated with the disease, wherein the patient administered the composition receives a therapeutic benefit. Also said (therapeutic) composition.

INTERNATIONAL SEARCH REPORT

International Application No

PCT/IB 01/01331

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9965517	A	23-12-1999	AU	4159399 A	05-01-2000
			EP	1085902 A2	28-03-2001
			WO	9965517 A2	23-12-1999
			US	2002048586 A1	25-04-2002
			ZA	9810275 A	12-06-2000
DE 19534630	A	20-03-1997	DE	19534630 A1	20-03-1997
WO 9965523	A	23-12-1999	AU	4159499 A	05-01-2000
			CA	2328504 A1	23-12-1999
			EP	1085905 A1	28-03-2001
			WO	9965523 A1	23-12-1999